Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...
The FDA has accepted a New Drug Application (NDA) for Celcuity’s gedatolisib in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2), PIK3CA wild-type advanced ...
The U.S. Food and Drug Administration (FDA) has accepted a new drug application for gedatolisib in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA ...
Gedatolisib's NDA for advanced breast cancer treatment has been accepted by the FDA, with a priority review and a PDUFA date ...
Prognostic value of hedgehog signaling in cervical carcinoma. Background: Although improvements in the treatment of ovarian cancer have increased the global prognosis, the metastatic disease is still ...
The intricate link between endocrine disorders and cancer development has drawn significant interest, revealing how conditions like insulin resistance and thyroid hormone imbalances contribute to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results